Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector

Journal of Virology

Volumn 75, Issue 18, 2001, Pages 8724-8732

  McGettigan, J P ^a   Sarma, S ^a   Orenstein, J M ^a   Pomerantz, R J ^a   Schnell, M J ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PROTEIN P55;

ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG RESPONSE; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RHABDOVIRUS; VIRUS EXPRESSION; VIRUS RECOMBINANT; VIRUS REPLICATION; WESTERN BLOTTING;

AIDS VACCINES; ANIMALS; FLOW CYTOMETRY; GENE EXPRESSION; GENE PRODUCTS, GAG; GENETIC VECTORS; HELA CELLS; HIV CORE PROTEIN P24; HIV-1; HUMANS; IMMUNIZATION; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; PROTEIN PRECURSORS; RABIES VIRUS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SYNTHETIC; VIRION; VIRUS REPLICATION;

EID: 0034881154     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.18.8724-8732.2001     Document Type: Article

References (52)

1. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone
2. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques
3. Systemic and mucosal immunity is elicited after both intramuscular and intravaginal delivery of human immunodeficiency virus type 1 DNA plasmid vaccines to pregnant chimpanzees
4. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
5. The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12
6. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus AIDS
7. Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections
8. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential foŕ virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter
9. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine
10. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector
11. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene
12. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles
13. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies
14. Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients
15. Virus promoters determine interference by defective RNAs: Selective amplification of mini-RNA vectors and rescue from cDNA by a 3′ copy-back ambisense rabies virus
16. A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection
17. Recombinant gp160 as a therapeutic vaccine for HIV-infection: Results of a large randomized, controlled trial
18. Generation of human monoclonal antibodies to human immunodeficiency virus
19. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS
20. Evidence for recombination of live, attenuated immunodeficiency virus vaccine with challenge virus to a more virulent strain
21. Envelope sequences of two new United States HIV-1 isolates
22. + cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins
23. Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector
24. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics
25. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
26. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions
27. Cross-clade recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection
28. Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates
29. Pathogenicity of different rabies virus variants inversely correlates with apoptosis and rabies virus glycoprotein expression in infected primary neuron cultures
30. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine
31. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type I infection
32. Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model
33. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV
34. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients
35. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection
36. Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts
37. Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 Gag by using DNA expression vectors that target Gag antigen to the secretory pathway
38. Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses
39. Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response
40. DNA vaccines for immunodeficiency viruses
41. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1
42. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women
43. Broadly cross-reactive HIV-specific cytotoxic T-lymphocytes in highly exposed persistently seronegative donors
44. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes
45. Recombinant rabies virus as potential live-viral vaccines for HIV-1
46. Reproducible plaquing system for rabies, lymphocytic choriomeningitis, and other ribonucleic acid viruses in BHK-21/13.S agarose suspensions
47. Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer
48. Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope
49. Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection
50. Genetic vaccines
51. Autointerference of rabies virus in chick embryo fibroblasts
52. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene